Genetic Sequence Data Analysis & Reporting Accelerated with Velsera's Release of CGW Plus
June 27 2024 - 11:16AM
Business Wire
Guiding Biomarker Quality and Evidence Reviews Transform
Clinical Genomics
Velsera, a leading global healthcare technology company offering
a universal software platform to connect clinical care with
discovery, is thrilled to announce the launch of CGW Plus, its
reimagined Clinical Genomics Workspace (CGW) platform. This update
introduces advanced variant quality and clinical evidence review
workflows, designed to simplify and accelerate the analysis and
reporting of genetic sequence data for clinical laboratory
professionals.
“With CGW Plus, we are setting a new standard in the clinical
genomics landscape,” said Rakesh Nagarajan, MD, PhD, Chief Medical
Officer at Velsera. “Our goal is to provide a seamless experience
for laboratory professionals, ensuring they have the most accurate
and comprehensive data at their fingertips. This not only enhances
workflow efficiency, but also improves the quality of patient care
through faster and more precise reporting.”
One of the standout features of CGW Plus is its expanded
clinical and biological evidence review capabilities. Leveraging
automated oncogenicity evaluations based on data from COSMIC,
ClinVar, and other sources, the platform helps streamline the
triaging of variants. The intuitive graphical filtering interface
allows users to quickly evaluate preconfigured filter logic and
perform targeted reviews without having to identify relevant
biomarkers using ad hoc, repetitive, and manual processes.
The reporting process is significantly streamlined with
automated draft interpretive text, which describes available
evidence and updates dynamically based on user decisions. This
feature is configurable to regional guidelines and drug label
sources, ensuring tailored and accurate reporting. Moreover, CGW
Plus supports comprehensive molecular results reporting, including
individual variants, co-occurring mutations, and other biomarkers
like tumor mutation burden (TMB) and microsatellite instability
(MSI). Non-NGS results such as immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH) can also be integrated
into the final report.
CGW Plus introduces adaptive learning and memory features,
allowing users to review all therapeutic, prognostic, and
diagnostic biomarker associations in a single view. Decisions made
once can be reused automatically in future cases within the same
disease context. Novelty alerts highlight previously interpreted
variants and draw attention to new or changed evidence,
facilitating efficient review and decision-making.
Innovative reporting capabilities are also a key highlight of
CGW Plus. The dynamic PDF report rendering feature enables users to
preview and finalize report content accurately and efficiently. The
location-aware clinical trial matching interface sorts trials based
on variant and tumor type, phase, and distance from the patient’s
location, helping clinicians quickly identify accessible and
promising options for investigational therapies.
CGW Plus offers a powerful and flexible variant table view,
equipping laboratory staff to rapidly review and triage variants
according to each assay’s performance characteristics and their
lab’s standard operating procedures. This is achieved by
pre-configuring filters based on analytical validation criteria and
facilitating deeper review of biomarkers in complex sequence
contexts.
In addition to these features, Velsera’s suite of
industry-leading clinical enablement and regulatory guidance
services will be available to CGW Plus customers. These
comprehensive service offerings include validation services,
revenue cycle management, medical director sign-out, and many
others to support clinical laboratory workflows.
About Velsera:
Velsera’s mission is to be the discovery, evidence generation,
and clinical delivery platform for precision medicine. We help
experts in clinical diagnostics and life sciences make better
decisions about providing the right therapy to the right patients
at the right time. Velsera was founded in 2023 as a result of the
merger of Seven Bridges, PierianDx and UgenTec and operates in the
US, Europe and Asia. For more information, visit
www.velsera.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627252718/en/
Brian Lassiter Manager, Commercial Marketing Velsera
Brian.lassiter@velsera.com (857) 357-3060 | ext 3060